CA2486270C - Vegfr modulating agents and methods for liver growth and liver protection - Google Patents

Vegfr modulating agents and methods for liver growth and liver protection Download PDF

Info

Publication number
CA2486270C
CA2486270C CA2486270A CA2486270A CA2486270C CA 2486270 C CA2486270 C CA 2486270C CA 2486270 A CA2486270 A CA 2486270A CA 2486270 A CA2486270 A CA 2486270A CA 2486270 C CA2486270 C CA 2486270C
Authority
CA
Canada
Prior art keywords
flt
agonist
vegf
liver
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2486270A
Other languages
English (en)
French (fr)
Other versions
CA2486270A1 (en
Inventor
Napoleone Ferrara
Kenneth J. Hillan
Jennifer Le Couter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2486270A1 publication Critical patent/CA2486270A1/en
Application granted granted Critical
Publication of CA2486270C publication Critical patent/CA2486270C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2486270A 2002-06-05 2003-06-05 Vegfr modulating agents and methods for liver growth and liver protection Expired - Fee Related CA2486270C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38663702P 2002-06-05 2002-06-05
US60/386,637 2002-06-05
PCT/US2003/017591 WO2003103581A2 (en) 2002-06-05 2003-06-05 Compositions and methods for liver growth and liver protection

Publications (2)

Publication Number Publication Date
CA2486270A1 CA2486270A1 (en) 2003-12-18
CA2486270C true CA2486270C (en) 2015-07-28

Family

ID=29736189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2486270A Expired - Fee Related CA2486270C (en) 2002-06-05 2003-06-05 Vegfr modulating agents and methods for liver growth and liver protection

Country Status (7)

Country Link
US (2) US7700571B2 (https=)
EP (2) EP2430923A1 (https=)
JP (2) JP5111729B2 (https=)
AU (1) AU2003251397B2 (https=)
CA (1) CA2486270C (https=)
IL (2) IL165392A0 (https=)
WO (1) WO2003103581A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP5111729B2 (ja) 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
ATE548447T1 (de) * 2004-01-14 2012-03-15 Novahep Ab Menschlicher hepatische vorläuferzellen und verfahren zur verwendung davon
US8070703B2 (en) * 2004-03-10 2011-12-06 Vision Quest Industries Incorporated Electrically stimulating orthotic device and segmented liner
WO2006014678A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
EP2447281B1 (en) 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
EP1904095B1 (en) 2005-06-30 2013-05-29 VIB, vzw Treatment of liver cirrhosis and its complications
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
AU2007230580A1 (en) * 2006-03-27 2007-10-04 Genentech, Inc. Methods for treating kidney disorders
US8685730B2 (en) * 2006-05-02 2014-04-01 Wisconsin Alumni Research Foundation Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
CN101250498B (zh) * 2008-04-07 2010-06-09 南通大学附属医院 用载肝细胞生长因子聚乳酸-o-羧甲基壳聚糖纳米粒子的肝细胞培养方法
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
ES2788300T3 (es) * 2010-11-09 2020-10-21 Univ Cornell Regeneración hepática
ES2424476T3 (es) * 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
KR102461927B1 (ko) * 2016-02-17 2022-10-31 차의과학대학교 산학협력단 이식용 줄기세포 및 이를 포함하는 혈관신생의 유도 또는 촉진을 위한 이식용 약학 조성물
CN114224893B (zh) * 2022-01-25 2023-06-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 喹唑啉衍生物在制备防治砷致肝损伤药物中的用途
CN116869986B (zh) * 2023-07-13 2025-12-02 南方医科大学 β-羟基丁酸在制备促进肝细胞增殖和肝脏再生产品方面的应用
TWI909652B (zh) 2023-08-31 2025-12-21 日商肽夢想股份有限公司 具有ｖｅｇｆｒ－２促效劑活性的肽複合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US6107046A (en) 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
DE69628652T3 (de) * 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2265931T3 (es) 1999-04-16 2007-03-01 Genentech, Inc. Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos.
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US20020164310A1 (en) * 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US6659223B2 (en) * 2001-10-05 2003-12-09 Collins & Aikman Products Co. Sound attenuating material for use within vehicles and methods of making same
JP5111729B2 (ja) * 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法

Also Published As

Publication number Publication date
EP1531676B1 (en) 2015-07-22
JP2005534648A (ja) 2005-11-17
EP1531676A4 (en) 2009-06-17
EP2430923A1 (en) 2012-03-21
HK1076227A1 (en) 2006-01-13
AU2003251397B2 (en) 2009-10-01
WO2003103581A3 (en) 2004-04-15
CA2486270A1 (en) 2003-12-18
EP1531676A2 (en) 2005-05-25
US20070122394A1 (en) 2007-05-31
WO2003103581A2 (en) 2003-12-18
US7700571B2 (en) 2010-04-20
AU2003251397A1 (en) 2003-12-22
US20040170613A1 (en) 2004-09-02
IL165392A (en) 2015-11-30
JP2010159266A (ja) 2010-07-22
JP5111729B2 (ja) 2013-01-09
US7709455B2 (en) 2010-05-04
IL165392A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
CA2486270C (en) Vegfr modulating agents and methods for liver growth and liver protection
Ferrara The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara et al. The biology of VEGF and its receptors
Giavazzi et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis
Hicklin et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
Mise et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
Niu et al. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy
Merrill et al. A reassessment of vascular endothelial growth factor in central nervous system pathology
JP2004307514A (ja) Ｈｇｆによる肝臓障害に対する保護
US20020102260A1 (en) Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
List et al. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase–dependent clonogenic response in acute myeloid leukemia cells
Mitchell et al. Angiogenesis in benign and malignant thyroid disease
Shan et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival
Ton et al. Resistance to anti-VEGF agents
EP1928907A2 (en) Vegf-activated fas ligands
Staton et al. Current status and future prospects for anti-angiogenic therapies in cancer
HK1076227B (en) Compositions and methods for liver growth and liver protection
Ribatti From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials
Ferrara Vascular endothelial growth factor: pathophysiology and clinical implications
KR20040004681A (ko) 혈관재생 요법
Pardali et al. Vegf signaling in normal and tumor angiogenesis
Donovan Vascular endothelial growth factor in breast cancer and novel anti-angiogenic mechanisms of tamoxifen
Schaffer et al. Hypoxia and hypothermia activate NF-kB through distinct cytoplasmic mechanisms with differential impact on cell viability in an in vitro primary rat hepatocyte model of cold hypoxia
Carrer AAV-mediated delivery of Semaphorin3A modifies tumor microenvironment and inhibits tumorigenesis in vivo
Enis Effects of anti-apoptotic and growth factor-signaling gene overexpression on vessel formation by transplanted human endothelial cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831